Cargando…
Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future
OBJECTIVE: To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis (RA)-associated coronary artery disease (CAD), and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen. DATA SOURCES:...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964948/ https://www.ncbi.nlm.nih.gov/pubmed/31855971 http://dx.doi.org/10.1097/CM9.0000000000000530 |
_version_ | 1783488556829769728 |
---|---|
author | Wang, Lun Zhang, Yang Zhang, Shu-Yang |
author_facet | Wang, Lun Zhang, Yang Zhang, Shu-Yang |
author_sort | Wang, Lun |
collection | PubMed |
description | OBJECTIVE: To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis (RA)-associated coronary artery disease (CAD), and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen. DATA SOURCES: This study was based on data obtained from PubMed up to May 2019 using various search terms and their combinations, including coronary artery disease, myocardial ischemia, cardiovascular diseases, RA, rheumatic diseases, treatment, therapy, strategies, immunotherapy, inflammation, and anti-inflammation. STUDY SELECTION: All retrieved literature was scrutinized, most relevant articles about the pathogenic mechanism and clinical management, especially anti-inflammatory therapy of RA-associated CAD were reviewed. RESULTS: RA is an immune-mediated chronic inflammatory disease which has a great social disease burden. In addition to typical arthritic manifestations, RA also affects extra-articular tissues and organs, within which the involvement of the cardiovascular system, especially incorporating CAD, is the leading cause of death for patients with RA. Recently, numerous basic and clinical studies have been carried out on the mechanism of CAD development and progression under the inflammatory cascade of RA. The effect of traditional RA drugs on CAD risk management has been gradually clarified, and more emerging biologic agents are being explored and studied, which have also achieved satisfactory outcomes. Furthermore, with the success of the CANTOS clinical trial, novel anti-inflammatory therapy for the prevention of cardiovascular disease is believed to have a broad prospect. CONCLUSIONS: RA is an independent risk factor for CAD, which mainly results from the underlying inflammatory cascade; therefore, anti-inflammatory therapy, especially the emerging novel biologic drugs, is important for CAD management in patients with RA and may also be a promising approach among the general population. |
format | Online Article Text |
id | pubmed-6964948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-69649482020-02-10 Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future Wang, Lun Zhang, Yang Zhang, Shu-Yang Chin Med J (Engl) Review Articles OBJECTIVE: To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis (RA)-associated coronary artery disease (CAD), and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen. DATA SOURCES: This study was based on data obtained from PubMed up to May 2019 using various search terms and their combinations, including coronary artery disease, myocardial ischemia, cardiovascular diseases, RA, rheumatic diseases, treatment, therapy, strategies, immunotherapy, inflammation, and anti-inflammation. STUDY SELECTION: All retrieved literature was scrutinized, most relevant articles about the pathogenic mechanism and clinical management, especially anti-inflammatory therapy of RA-associated CAD were reviewed. RESULTS: RA is an immune-mediated chronic inflammatory disease which has a great social disease burden. In addition to typical arthritic manifestations, RA also affects extra-articular tissues and organs, within which the involvement of the cardiovascular system, especially incorporating CAD, is the leading cause of death for patients with RA. Recently, numerous basic and clinical studies have been carried out on the mechanism of CAD development and progression under the inflammatory cascade of RA. The effect of traditional RA drugs on CAD risk management has been gradually clarified, and more emerging biologic agents are being explored and studied, which have also achieved satisfactory outcomes. Furthermore, with the success of the CANTOS clinical trial, novel anti-inflammatory therapy for the prevention of cardiovascular disease is believed to have a broad prospect. CONCLUSIONS: RA is an independent risk factor for CAD, which mainly results from the underlying inflammatory cascade; therefore, anti-inflammatory therapy, especially the emerging novel biologic drugs, is important for CAD management in patients with RA and may also be a promising approach among the general population. Wolters Kluwer Health 2019-12-20 2019-12-20 /pmc/articles/PMC6964948/ /pubmed/31855971 http://dx.doi.org/10.1097/CM9.0000000000000530 Text en Copyright © 2019 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Review Articles Wang, Lun Zhang, Yang Zhang, Shu-Yang Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future |
title | Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future |
title_full | Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future |
title_fullStr | Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future |
title_full_unstemmed | Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future |
title_short | Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future |
title_sort | immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964948/ https://www.ncbi.nlm.nih.gov/pubmed/31855971 http://dx.doi.org/10.1097/CM9.0000000000000530 |
work_keys_str_mv | AT wanglun immunotherapyfortherheumatoidarthritisassociatedcoronaryarterydiseasepromiseandfuture AT zhangyang immunotherapyfortherheumatoidarthritisassociatedcoronaryarterydiseasepromiseandfuture AT zhangshuyang immunotherapyfortherheumatoidarthritisassociatedcoronaryarterydiseasepromiseandfuture |